Systematic pharmacology analysis of Sodium 8-(((carboxymethyl)amino)methyl)-4’,7-bishydroxy-isoflavone-3’-sulfonate
Drug Combination Therapy. 2019, 1 (4): 186-198.
The purpose of this study is to use the newly synthesized molecule Sodium 8-(((carboxymethyl)amino)methyl)-4’,7-bishydroxy-isoflavone-3’-sulfonate (M) as a research object, the pharmacological mechanism of the molecule was analyzed by using a series of Systematic pharmacology methods. The results show that the M molecule has a higher drug-like DL value of 0.59 and better molecular property parameters, namely Hdon=4, Hacc=10 and AlogP=0.94; A total of 11 M molecules related targets, namely F2, ESR1, AR, F10, CA2, DPP4, CCNA2, PRSS1, CDK2, GSK3B and PTPN1; A total of 140 diseases are associated with M molecule targets, and these diseases are mainly related to cancer and cardiovascular diseases; A total of 52 pathways involve the pharmacological mechanisms of M molecules, which are mainly related to cancer and other related diseases; GO-enriched analysis showed that these targets are closely related to the regulation of peptidase activity and biological processes such as blood coagulation and hemostasis. This article clearly demonstrated the pharmacological mechanism of M molecule, which provides references for exploring the pharmacological mechanism of new compounds.
A Meta-analysis of the efficacy and safety of Kanglaite injection combined with chemotherapy in the treatment of pancreatic cancer
Drug Combination Therapy. 2019, 1 (4): 210-223.
Objective: To investigate the
efficacy and safety of Kanglaite injection (KLT) combined with chemotherapy in
the treatment of pancreatic cancer. Methods: PubMed,
EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI),
Wanfang Database, VIP Data, and Chinese
Biomedical Database (CBM) were searched to get the studies about KLT plus chemotherapy
for pancreatic cancer (from established to May 2019) . Data extraction and bias risk assessment were
carried out by two authors independently according to the retrieval method. RevMan
(version 5.3) were employed for data analysis. Results: A total of 151
literatures were retrieved and 11 literatures were finally included. A total of
614 patients were included, including 308 in the treatment group and 306 in the
control group. The results of meta-analysis showed that compared with
chemotherapy alone, KLT combined with chemotherapy could improve the effective
rate [ P ORR = 0.0009, OR=1.96,
95% CI (1.32, 2.92)] and disease control rate [ P DCR <0.00001, OR=2.53, 95% CI (1.76, 3.62)], improve
KPS score [ P <0.00001, OR=3.59, 95%
CI (2.00, 6.44)] and body mass indexes [ P =0.0003,
OR=3.45, 95% CI (1.78, 6.69)], prolong progression free survival (PFS) and overall
survival (OS), reduce the rate of myelosuppression [ P =0.03, OR=0.54, 95% CI (0.30, 0.95)], but could not reduce the
occurrence of neurotoxicity [ P =0.49,
OR=0.80, 95% CI (0.42, 1.51)] and digestive tract reaction [ P =0.51, OR=0.83, 95% CI (0.48, 1.44)]. Conclusion: KLT combined with chemotherapy can improve the curative effect of
pancreatic cancer, improve the quality of life of patients, prolong the
survival of patients, and reduce the incidence of bone marrow suppression.
However, due to the limitation of the quality and quantity of included
literatures, this conclusion needs to be verified by high-quality study.
Systematic evaluation and meta-anlysis of the efficacy of Xiaochaihu Decoction in the treatment of chronic superficial gastritis
Drug Combination Therapy. 2019, 1 (4): 224-236.
compare the effectiveness of Xiaochaihu Decoction (XCHD) or the modified XCHD
combined with western medicine in the treatment of superficial gastritis. Methods: We collected the studies about XCHD or the modified XCHD combined with western
medicine for superficial gastritis in China Biology Medicine (CBM) Database
(2010-2018), China National Knowledge Infrastructure (CNKI) Database
(2010-2018), VIP Database (2010-2018), Wanfang Database (2010-2018) and the
Back Issues Database of Hebei University. The randomized controlled trials
(RCTs) were included in this study. The literatures were independently
extracted by two researchers and the Cochrane Review Handbook (version 5.1.0)
was applied to assess the quality of included trials. Statistical analysis was
performed with RevMan (version 5.3). Results: A total of 8 RCTs,
including 732 cases, were included finally. Meta-analysis results showed that
compared with the western medicine treatment group, XCHD or the modified XCHD
combined with western medicine could improve the total effective rate [OR=4.67,
95%CI (2.90,7.55), P <0.00001], physiological
function [MD=10, 95%CI (8.78,11.23), P <0.00001],
role physical [MD=13.85, 95%CI (11.19,16.51), P <0.00001], physical pain [MD=11.64, 95%CI (9.05,14.23), P <0.00001], general health [MD=11.20,
95%CI (9.52,12.88), P <0.00001],
vitality [MD=13.46, 95%CI (12.30,14.62), P <0.00001],
social function [MD=19.20, 95%CI (17.32,21.09), P <0.00001], affection function [MD=30.3, 95%CI (28.99,31.62), P <0.00001], mental health [MD=9.80, 95%CI (8.44,11.16), P <0.00001]. Conclusion: XCHD
or the modified XCHD combined with western medicine in the treatment of
superficial gastritis has good performance in clinical efficacy and the
improvement of quality of life. However, with several methodology problems
existing in the included RCTs, the effectiveness of XCHD or the modified XCHD
is still need more high-quality randomized, double-blind, placebo-controlled
trials to further confirmed.
Research progress of Yinchenhao Decoction in the treatment of non-alcoholic fatty liver disease
Drug Combination Therapy. 2019, 1 (4): 237-244.
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Non-alcoholic steatohepatitis (NASH) is the most serious type and a turning point in the progression of NAFLD. If not treated actively, NASH will progress to irreversible liver damage such as cirrhosis and hepatocellular carcinoma. At present, there are no specific therapeutic drugs in western medicine. The treatment methods are mainly to improve lifestyle and exercise therapy, to alleviate the symptoms of discomfort, delay the progress of the disease, and improve the quality of life. However, the effect is often not ideal, prone to recurrence, and compliance is relatively poor. Dramatically, traditional Chinese medicine has certain advantages in the treatment of NAFLD. Modern research has confirmed that Yinchenhao Decoction has a good effect on liver-protective and choleretic action and improving liver function. It has significant curative effect on various liver and gallbladder diseases such as acute liver injury and alcoholic liver disease. This article summarized the clinical and basic research of Yinchenhao Decoction in the treatment of NAFLD. We found that Yinchenhao Decoction can enhance the efficiency of NAFLD and improve symptoms such as dizziness, liver pain, hepatosplenomegaly and indigestion. The mechanisms may be related to that Yinchenhao decoction improves the disorder of glucose and lipid metabolism, inflammatory state and liver function.